Jade Biosciences (JBIO) Competitors

Jade Biosciences logo
$15.40 +0.06 (+0.39%)
Closing price 04:00 PM Eastern
Extended Trading
$15.44 +0.04 (+0.26%)
As of 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

JBIO vs. RLAY, XENE, AMLX, GMTX, and LEGN

Should you buy Jade Biosciences stock or one of its competitors? Jade Biosciences's main competitors and comparable companies include Relay Therapeutics (RLAY), Xenon Pharmaceuticals (XENE), Amylyx Pharmaceuticals (AMLX), Gemini Therapeutics (GMTX), and Legend Biotech (LEGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jade Biosciences compare to Relay Therapeutics?

Jade Biosciences (NASDAQ:JBIO) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Jade Biosciences presently has a consensus price target of $51.00, indicating a potential upside of 232.46%. Relay Therapeutics has a consensus price target of $27.00, indicating a potential upside of 56.34%. Given Jade Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Jade Biosciences is more favorable than Relay Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Relay Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86

Jade Biosciences has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Jade Biosciences has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jade BiosciencesN/AN/A-$127.41M-$1.86N/A
Relay Therapeutics$15.35M248.60-$276.48M-$1.51N/A

Relay Therapeutics' return on equity of -40.25% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jade BiosciencesN/A -49.11% -45.62%
Relay Therapeutics N/A -40.25%-36.82%

In the previous week, Relay Therapeutics had 1 more articles in the media than Jade Biosciences. MarketBeat recorded 13 mentions for Relay Therapeutics and 12 mentions for Jade Biosciences. Relay Therapeutics' average media sentiment score of 0.96 beat Jade Biosciences' score of 0.55 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Relay Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

97.0% of Relay Therapeutics shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Relay Therapeutics beats Jade Biosciences on 8 of the 15 factors compared between the two stocks.

How does Jade Biosciences compare to Xenon Pharmaceuticals?

Jade Biosciences (NASDAQ:JBIO) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Jade Biosciences currently has a consensus price target of $51.00, suggesting a potential upside of 232.46%. Xenon Pharmaceuticals has a consensus price target of $71.31, suggesting a potential upside of 81.63%. Given Jade Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Jade Biosciences is more favorable than Xenon Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Xenon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jade Biosciences has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market.

Xenon Pharmaceuticals' return on equity of -39.81% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jade BiosciencesN/A -49.11% -45.62%
Xenon Pharmaceuticals N/A -39.81%-37.98%

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Jade Biosciences. MarketBeat recorded 14 mentions for Xenon Pharmaceuticals and 12 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.55 beat Xenon Pharmaceuticals' score of 0.01 indicating that Jade Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Xenon Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Jade Biosciences has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jade BiosciencesN/AN/A-$127.41M-$1.86N/A
Xenon Pharmaceuticals$7.50M506.04-$345.91M-$4.70N/A

Summary

Jade Biosciences beats Xenon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Amylyx Pharmaceuticals?

Jade Biosciences (NASDAQ:JBIO) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Jade Biosciences currently has a consensus price target of $51.00, suggesting a potential upside of 232.46%. Amylyx Pharmaceuticals has a consensus price target of $43.71, suggesting a potential upside of 57.25%. Given Jade Biosciences' higher probable upside, equities analysts plainly believe Jade Biosciences is more favorable than Amylyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90
Amylyx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jade Biosciences has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market.

Amylyx Pharmaceuticals' return on equity of -41.54% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jade BiosciencesN/A -49.11% -45.62%
Amylyx Pharmaceuticals N/A -41.54%-38.91%

In the previous week, Jade Biosciences had 2 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 12 mentions for Jade Biosciences and 10 mentions for Amylyx Pharmaceuticals. Jade Biosciences' average media sentiment score of 0.55 beat Amylyx Pharmaceuticals' score of 0.37 indicating that Jade Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jade Biosciences
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Amylyx Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Jade Biosciences has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jade BiosciencesN/AN/A-$127.41M-$1.86N/A
Amylyx Pharmaceuticals$87.37M40.91-$144.74M-$1.44N/A

Summary

Jade Biosciences and Amylyx Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Jade Biosciences compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Jade Biosciences has a consensus price target of $51.00, suggesting a potential upside of 232.46%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Gemini Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gemini Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90

In the previous week, Jade Biosciences had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 12 mentions for Jade Biosciences and 0 mentions for Gemini Therapeutics. Jade Biosciences' average media sentiment score of 0.55 beat Gemini Therapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Gemini Therapeutics Neutral
Jade Biosciences Positive

Gemini Therapeutics' return on equity of -38.78% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Gemini TherapeuticsN/A -38.78% -35.88%
Jade Biosciences N/A -49.11%-45.62%

Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/A-$71.87M-$1.00N/A
Jade BiosciencesN/AN/A-$127.41M-$1.86N/A

75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Jade Biosciences beats Gemini Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Jade Biosciences compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Jade Biosciences (NASDAQ:JBIO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Legend Biotech currently has a consensus target price of $50.85, suggesting a potential upside of 217.99%. Jade Biosciences has a consensus target price of $51.00, suggesting a potential upside of 232.46%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Jade Biosciences is more favorable than Legend Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90

Legend Biotech has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Jade Biosciences has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Legend Biotech$1.03B3.01-$296.80M-$0.01N/A
Jade BiosciencesN/AN/A-$127.41M-$1.86N/A

In the previous week, Legend Biotech had 22 more articles in the media than Jade Biosciences. MarketBeat recorded 34 mentions for Legend Biotech and 12 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.55 beat Legend Biotech's score of -0.09 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Legend Biotech
2 Very Positive mention(s)
5 Positive mention(s)
10 Neutral mention(s)
9 Negative mention(s)
2 Very Negative mention(s)
Neutral
Jade Biosciences
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Jade Biosciences has a net margin of 0.00% compared to Legend Biotech's net margin of -0.02%. Legend Biotech's return on equity of -0.03% beat Jade Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Legend Biotech-0.02% -0.03% -0.02%
Jade Biosciences N/A -49.11%-45.62%

Summary

Jade Biosciences beats Legend Biotech on 8 of the 15 factors compared between the two stocks.

Get Jade Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for JBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JBIO vs. The Competition

MetricJade BiosciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.06B$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A25.6832.7626.82
Price / SalesN/A16.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book2.344.184.463.72
Net Income-$127.41M-$24.15M$3.52B$393.10M
7 Day Performance-6.10%-7.25%-5.47%-4.73%
1 Month Performance14.33%-5.98%-4.57%-7.14%
1 Year Performance22.32%-7.72%-1.79%-7.51%

Jade Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JBIO
Jade Biosciences
2.7485 of 5 stars
$15.40
+0.4%
$51.00
+231.2%
+43.4%$1.06BN/AN/A55
RLAY
Relay Therapeutics
2.7808 of 5 stars
$18.08
-8.3%
$27.00
+49.3%
+174.6%$3.99B$10.35MN/A218
XENE
Xenon Pharmaceuticals
3.0202 of 5 stars
$40.99
-2.6%
$71.31
+74.0%
-3.7%$3.96B$7.50MN/A364
AMLX
Amylyx Pharmaceuticals
3.1599 of 5 stars
$29.86
-6.1%
$43.71
+46.4%
+119.1%$3.84BN/AN/A136
GMTX
Gemini Therapeutics
N/A$87.08
+2.9%
N/A-11.1%$3.77BN/AN/A30

Related Companies and Tools


This page (NASDAQ:JBIO) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners